Division of Chemo Group
Latest From Exeltis Pharma
Generics firms barred from European markets by injunctions granted on patents that are subsequently found to be invalid are not automatically entitled to damages from the originator, the CJEU has ruled in a Hungarian case involving Gedeon Richter, Exeltis and Bayer.
Firms that achieved recognition at last year’s Global Generics & Biosimilars Awards have continued to build on that success in the months since.
Alvogen has struck a deal with Insud’s Exeltis to gain rights to 23 women’s healthcare brands in Russia, Ukraine and Kazakhstan.
- Therapeutic Areas
- Gynecological, Urological
- Neurology, Nervous System
- Respiratory, Pulmonary
- Southeast Asia
- Parent & Subsidiaries
- Chemo Group
- Senior Management
- Contact Info
S-12A-5, South Tower, , First Subang
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.